CTKB vs AZTA

For growth investors, Azenta, Inc.

(AZTA) is the stronger pick with 3. 6% revenue growth year-over-year, versus 0. 5% for Cytek Biosciences, Inc. (CTKB). Analysts rate Cytek Biosciences, Inc. (CTKB) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cytek Biosciences, Inc.

(CTKB) delivered a total return of -75. 4%, compared to -78. 2% for Azenta, Inc. (AZTA). Over 10 years, the gap is even starker: AZTA returned +130. 4% versus CTKB's -75. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cytek Biosciences, Inc.

(CTKB) is the lower-risk stock at 1. 66β versus Azenta, Inc. 's 1. 91β — meaning AZTA is approximately 15% more volatile than CTKB relative to the S&P 500. On balance sheet safety, Azenta, Inc. (AZTA) carries a lower debt/equity ratio of 6% versus 7% for Cytek Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Azenta, Inc.

(AZTA) is pulling ahead at 3. 6% versus 0. 5% for Cytek Biosciences, Inc. (CTKB). On earnings-per-share growth, the picture is similar: Azenta, Inc. grew EPS 60. 5% year-over-year, compared to -1028. 0% for Cytek Biosciences, Inc.. Over a 3-year CAGR, CTKB leads at 7. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Azenta, Inc.

(AZTA) is the more profitable company, earning -9. 4% net margin versus -33. 0% for Cytek Biosciences, Inc. — meaning it keeps -9. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZTA leads at -1. 9% versus -20. 0% for CTKB. At the gross margin level — before operating expenses — CTKB leads at 51. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AZTA: 132.

4% to $44. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cytek Biosciences, Inc.

(CTKB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Azenta, Inc. (AZTA) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTKB: -75. 4%, AZTA: +130. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.